Media Coverage

Advanced Search
  • 07232024

    Quest Diagnostics raised its 2024 profit and revenue forecasts on Tuesday, banking on robust demand for its health tests. Demand for diagnostic tests has grown in recent quarters as more people, especially older adults, caught up on surgeries deferred during the pandemic. "This performance is due to growth of new physician and hospital customers, more favorable test mix that includes greater adoption of advanced diagnostics," Quest CEO Jim Davis said.

  • 07162024

    Here’s what experts say your AMH level can and can’t tell you about your fertility. “An AMH test could be the first step. Anything that initiates discussions between you and your spouse or your significant other and your health care professional I think is incredibly valuable,” says Damian Alagia, MD, Senior Medical Director for Advanced Diagnostics and Women’s Health at Quest Diagnostics on behalf of

  • 07102024
    Becker's Hospital Review

    OhioHealth, based in Columbus, signed an agreement to sell certain assets of its outreach laboratory services business to Quest Diagnostics. The parties expect the transaction to close in the third quarter of the year, pending regulatory approval. Financial terms of the agreement were not disclosed.

  • 07032024

    Quest Diagnostics said on Wednesday it would acquire Canada-based LifeLabs from pension plan owner OMERS for about C$1.35 billion, or about $985 million, including net debt. LifeLabs, which provides community laboratory tests, would retain its brand, Canadian headquarters and management after the acquisition is closed. The U.S. laboratory operator will acquire 100% of the equity of LifeLabs and expects to fund the acquisition through cash on hand and debt. Quest expects the deal to generate roughly $710 million in annual revenues.

  • 06272024
    Modern Healthcare

    Quest Diagnostics plans to acquire Allina Health's laboratory assets at most of its ambulatory clinic sites. The company and the Minneapolis-based health system have signed an definitive agreement and expect the transaction to close this fall, pending regulatory approvals. Financial terms were not disclosed.

  • 06052024

    If it feels like you’ve been hearing more about testosterone lately, you’re not wrong. However, the question of whether or not you should get your own testosterone checked isn’t so straightforward. To put it simply, if you’re not experiencing persistent symptoms associated with low testosterone, you have no reason to get your levels checked—regardless of what they might be. “If you're otherwise feeling well, I really don't advocate just going on a fishing expedition,” says Sanjay B. Dixit, MD, medical director of cardiometabolic endocrine and wellness clinical solutions at Quest Diagnostics. “That's actually one of the key points in the Endocrine Society’s guidelines from 2018, that they do not recommend testing in otherwise asymptomatic men.”

  • 06042024
    Contagion Live

    Despite the national hepatitis C elimination goals for 2030 to achieve at least 80% of persons with hepatitis C to achieve viral clearance, the goals across states is consistently falling under. In fact, analysis of data collected during 2013–2022 from a national laboratory found that HCV clearance or cure proportions among persons with virus by state was between 10% to 51%.1This data was published in the Centers for Disease Control’ and Prevention's (CDC) MMWR late last week. The investigators collected 10 years of data from January 1, 2013 through December 31, 2022 utilizing information from the national laboratory company, Quest Diagnostics. They analyzed patients from all 50 states and the District of Columbia.

  • 06032024
    Medical Laboratory Observer

    A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery for stage II colorectal cancer, according to a study published in JAMA Health Forum, a member of the JAMA Network. Researchers from Haystack Oncology, a Quest Diagnostics company and developer of the Haystack MRD tumor-informed ctDNA MRD technology, City of Hope and the Walter and Eliza Hall Institute of Medical Research conducted the study. In June 2022, a randomized clinical trial (DYNAMIC) demonstrated that a tumor-informed ctDNA MRD test performed on patients with stage II colorectal cancer reduced the application of adjuvant chemotherapy (ACT) by nearly half (15% vs. 28%) without compromising recurrence-free survival.

  • 05152024
    The Wall Street Journal

    Workers are cheating on drug tests at the highest rate in more than 30 years, according to one of the U.S.’s largest drug-testing labs. The increase in tampered tests came from samples collected in 2023. About 31,000 drug screens out of 5.5 million showed signs of cheating, according to Quest Diagnostics. “Some American workers are going to great lengths to attempt to subvert the drug-testing process,” said Dr. Suhash Harwani, senior director of science for workforce health solutions at Quest. The percentage of urine samples that came back positive for drugs among the U.S. workforce remained steady at a two-decade high for the third year in a row. But the substantial rise of tampering, as well as the patchwork of new marijuana laws across the U.S., have intensified challenges for employers seeking to keep drugs out of the workplace.

  • 05012024
    Fierce Biotech

    Quest Diagnostics is building out its artificial intelligence-powered cancer pathology offerings through a multi-layered deal with PathAI—acquiring some assets, licensing out others. The testing giant will be buying out PathAI’s Memphis, Tennessee-based diagnostics laboratory, with plans to turn it into its own AI and digital R&D solutions center to help support its current AmeriPath and Dermpath Diagnostics pathology businesses.